Strategic partnerships Presage already collaborates with major pharma players such as Takeda, Celgene, and Bristol-Myers Squibb, indicating a receptive ecosystem for continued Phase 0 collaborations. Sales opportunities exist in expanding co-development or multi-drug testing programs with these networks and their oncology portfolios.

Clinical expansion Recent and ongoing collaborations, including a landmark melanoma trial with UZ Leuven and VIB-KU Leuven, demonstrate capacity to scale Phase 0 programs across geographies and cancer indications. This presents opportunities to offer our CIVO-enabled testing to additional academic centers and regional cancer networks seeking early drug evaluation.

Financial potential With revenue in the low-to-mid single digits and substantial funding, Presage appears positioned to invest in expanded services, regulatory-ready pathways, and broader site networks. Sales focus can target biopharma partners seeking reduced clinical risk and accelerated early-phase decision-making.

Technical enablement The current tech stack and cloud-enabled operations support scalable trial deployment and data capture. This capability can be framed as a differentiator for pharma partners aiming to integrate CIVO data into their decision engines and accelerate 후보 drug prioritization pipelines.

Market readiness There is a clear emphasis on Phase 0 strategies with established feasibility and trained clinical sites. Business development can pursue tier-1 oncology companies looking to de-risk early asset evaluation, as well as CROs seeking to augment their Phase 0 offerings with a validated, patient-based testing modality.